Tagged with Strategy

Medtech Saudi Arabia is seeing an increased demand for more innovative medical devices and a greater awareness of the myriad ways that medical technology can be used for screening illnesses such as cardiovascular disease, cancer and diabetes. Stakeholders from three multinational medtech firms commented on their strategies for growth in this…

Amgen Alper Ureten, Amgen VP and General Manager, sits down with PharmaBoardroom to set out his ambitions and objectives for its Biosimilars Business Unit. Ureten also reveals the strategy behind their success with biosimilars and emphasises the need for competition and high quality to foster eco-system maturity.   The key priority…

Data New approaches to pharma sales: Marrying data analytics with the art of personal engagement   The lock-down impact for COVID-19 was stark, looking at available March data cuts from IQVIA which signal serious additional healthcare consequences beyond infected patients. A decline of 72% of in-person doctor visits, -70% Rx volume,…

Belgium Philippe de Pougnadoresse, country president & general manager pharma for Novartis Belgium & Luxembourg, outlines his affiliate’s fast and comprehensive response to the COVID-19 crisis, what can be learned from it, the importance of Belgium to the European group, and the challenges of launching gene therapy Zolgensma® in Belgium.  …

Belgium Christophe Van Damme, vice president and general manager of Perrigo Belgium and Luxembourg, shines a light on the transformation for Perrigo since its acquisition of Omega Pharma in 2015. Van Damme also explains Perrigo’s strategy for growth, the impact, opportunities, and challenges of the COVID-19 crisis, and how the self-care…

Merck Merck KGaA has moved to continuously expand its manufacturing capacity and capability in recent years with a number of headline-grabbing investments in sites in its home market of Germany and across the world. Moreover, the company is now increasingly at the forefront of digitalisation and innovation in its manufacturing and…

USA Dr Brett Monia, co-founder and CEO of RNA therapeutics pioneer Ionis Pharmaceuticals, outlines the company’s extremely promising development pipeline, commercial partnerships with Big Pharma, and his ambitious strategy to launch ten or more products by 2025.   We have many programs currently in Phase III development. All these medicines are…

USA Christopher Posner, US head for Danish medical dermatology specialist LEO Pharma, outlines how a mid-sized European company navigates the US market’s complex access and affordability issues, the innovations that the company is bringing to the US, and his leadership and HR philosophy.   My priority leading LEO Pharma Inc. in…

Belgium Veronique Walsh, General Manager of Bristol Myers Squibb (BMS) – Benelux, explains her ambition to build a new company culture following the acquisition of Celgene. Walsh also lays bare the prospects for bringing innovation to Belgian patients and explains how BMS continues to deliver on its promise of transforming lives…

Korea Kyung Suk Kim, CEO of Corestem, the first company to receive approval for a stem cell therapy for Amyotrophic Lateral Sclerosis (ALS) in Korea, recounts the firm’s main achievements since her previous interview with PharmaBoardroom in 2018. Dr Kim unveils Corestem’s new strategy to prioritise the US market and offers…

Global ‘The Key Challenges: Life Sciences and Healthcare 2020’ is the latest report from Cornerstone International Group based on a global survey of stakeholders from across the life sciences healthcare (LSH) industry. The following is an extract on strategy. Click here to read the full report.   Compared to other businesses,…

France David Loew, formerly executive vice president of Sanofi Pasteur, Sanofi’s vaccines division, was appointed CEO of fellow French firm Ipsen on the 28th May 2020, effective 1st July.   Loew, who spoke to PharmaBoardroom in January 2019 while in position at Sanofi Pasteur, is taking the helm from Aymeric Le…